OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Wang on the Results of the ZUMA-2 Trial in Relapsed/Refractory MCL

May 8th 2020

Michael Wang, MD, discusses the results of the phase 2 ZUMA-2 trial in relapsed/refractory mantle cell lymphoma.

Dr. Shinohara on Pairing SBRT With Immunotherapy in Prostate Cancer

May 8th 2020

Eric Shinohara, MD, MSCI, discusses the potential to combine stereotactic body radiotherapy with immunotherapy in prostate cancer.

Dr. Monk on the Significance of Bevacizumab in Cervical Cancer

May 8th 2020

Bradley J. Monk, MD, FACS, FACOG, discusses the FDA approval of bevacizumab and other novel agents in cervical cancer.

Dr. Raphael on the Clinical Implications of the CLL14 Trial

May 8th 2020

Bruce G. Raphael, MD, discusses the utility of venetoclax and obinutuzumab in chronic lymphocytic leukemia.

Dr. Saba on Unique Set of Challenges Caused By COVID-19 in Head and Neck Cancer

May 7th 2020

Nabil F. Saba, MD, FACP, discusses how the COVID-19 pandemic has impacted treatment in head and neck cancer and the health care system at large.

DNA-PK as an Emerging Target in Prostate Cancer

May 7th 2020

Karen E. Knudsen, PhD, chair and Hilary Koprowski Professor, Department of Cancer Biology, professor of cancer biology, urology, medical oncology, and radiation oncology, and enterprise director, Sidney Kimmel Cancer Center, Thomas Jefferson University Hospital, discusses DNA-dependent protein kinase (DNA-PK) as an emerging target in prostate cancer.

Dr. Choi on Emerging Treatments in CLL

May 7th 2020

Michael Choi, MD, a medical staff physician and associate clinical professor of medicine at the University of California, San Diego (UCSD) Medical Center, discusses emerging treatments in chronic lymphocytic leukemia (CLL).

Dr. Barr on Novel Combination Strategies in CLL

May 7th 2020

Paul M. Barr, MD, Wilmot Cancer Institute, University of Rochester, discusses novel combination strategies in chronic lymphocytic leukemia (CLL).

Dr. Pagel on the Shift Toward Precision Medicine in Large Cell Lymphoma

May 7th 2020

John M. Pagel, MD, PhD, chief of the Hematologic Malignancies Program, and director, Hematopoietic Cell Transplantation Program, at Swedish Cancer Institute, discusses the shift toward precision medicine in large cell lymphoma.

Dr. Gomella on the Evolution of Genetic Testing in Prostate Cancer

May 7th 2020

Leonard G. Gomella, MD, professor, chair of the Department of Urology, and director of the Sidney Kimmel Cancer Center Network, of Thomas Jefferson University Hospital, discusses the evolution of genetic testing in prostate cancer.

Dr. Cone on Research Investigating Cardiac Toxicity of GnRH Agonists/Antagonists in Prostate Cancer

May 7th 2020

Eugene B. Cone, MD, a urologic oncology fellow at Brigham and Women’s Hospital and Massachusetts General Hospital, discusses research investigating the cardiac toxicity of gonadotropin-releasing hormone (GnRH) agonists and antagonists in prostate cancer.

Dr. Agarwal on Data With Cabozantinib/Atezolizumab in mCRPC

May 7th 2020

Neeraj Agarwal, MD, director of the Genitourinary Oncology Program, Oncology Division, professor of medicine, physician, and investigator, at Huntsman Cancer Institute, discusses data with the combination of cabozantinib (Cabometyx) and atezolizumab (Tecentriq) in patients with metastatic castration-resistant prostate cancer (mCRPC).

Dr. Miklos on Alternative Options to KTE-X19 in MCL, While Awaiting FDA Decision

May 7th 2020

David Miklos, MD, discusses alternative options to the investigational CAR T-cell therapy KTE-X19 for patients with relapsed/refractory mantle cell lymphoma, while awaiting a regulatory decision from the FDA.

Dr. Simeone on Benefit of Neoadjuvant Gemcitabine in Pancreatic Cancer

May 7th 2020

Diane M. Simeone, MD, discusses the benefit of using a gemcitabine “sandwich approach” in patients with resectable pancreatic cancer.

Dr. Crew on Recent Advances in HER2+ Breast Cancer

May 7th 2020

Katherine D. Crew, MD, MS, discusses recent advances made in HER2-positive breast cancer treatment.

Dr. Tolaney on Sequencing Strategies in Metastatic HER2+ Breast Cancer

May 6th 2020

Sara M. Tolaney, MD, MPH, discusses sequencing strategies in metastatic HER2-positive breast cancer.

Dr. Pagel on Ongoing Research With BTK Inhibitors in CLL

May 6th 2020

John M. Pagel, MD, PhD, chief of the Hematologic Malignancies Program, and director, Hematopoietic Cell Transplantation Program, at Swedish Cancer Institute, discusses ongoing research with BTK inhibitors in chronic lymphocytic leukemia (CLL).

Dr. Naumann on Unanswered Questions With PARP Inhibitors in Ovarian Cancer

May 6th 2020

R. Wendel Naumann, MD, gynecologic oncologist, Levine Cancer Institute, Carolinas HealthCare System/Atrium Health, discusses unanswered questions with PARP inhibitors in ovarian cancer.

Dr. Overman on Ongoing Research With Immunotherapy in Microsatellite Stable CRC

May 6th 2020

Michael J. Overman, MD, professor in the Department of Gastrointestinal Medical Oncology of the Division of Cancer Medicine and committee vice chair at The University of Texas MD Anderson Cancer Center, discusses ongoing research with immunotherapy in microsatellite stable (MSS) colorectal cancer (CRC).

Dr. Ocean on Combating the Emotional Toll Caused by COVID-19 in Cancer

May 6th 2020

Allyson Ocean, MD, discusses the emotional toll COVID-19 has had on patients and practitioners in the oncology space and the importance of self-care and social distancing.